The global demand for Hospital Acquired Disease Testing Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022-2028.
Hospital-acquired disease testing involves the diagnosis of diseases contracted from microbial infections or toxins in a healthcare facility. The intensive care unit is the most common location in a hospital where anyone can contract an illness, increasing morbidity, mortality, and hospital costs. The most common diseases tested include surgical site infections, gastroenteritis, pneumonia, meningitis, and urinary tract infections. The primary cause of these diseases is unclean hands, medical instruments such as catheters, respiratory machines, and excessive or improper use of antibiotics. The testing for these diseases involves diagnosis by sight and symptoms alone and can appear within 48 hours of admission, three days after discharge, or 30 days after an operation.
Market Dynamics
Lack of poor hygiene and the emergence of drug-resistant organisms in healthcare facilities will be the vital stimulating agents for this market's growth. Increasing the geriatric population and inflating morbidity rates among patients undergoing treatment for chronic diseases in a healthcare facility will boost this market's growth. Technological advancements in the healthcare industry and novel diagnostic techniques and tools will benefit this market's growth. Better surveillance cultures to detect unseen pathogens in colonized patients and prevent transmission of infections will be a market booster. The lack of budget, skilled labor and stringent government regulations will be a few hindrances not favorable to market growth.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of hospital acquired disease testing.
Market Segmentation
This section of the hospital acquired disease testing market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Test Type
- Urinary Tract Infection
- Surgical Site Infection
- Pneumonia Stents
- Blood Stream Infection
- Methicillin-resistant Staphylococcus Aureus
By End User
- Hospitals and Intensive Care Units (ICUS)
- Ambulatory Surgical and Diagnostic Centers
- Nursing Homes and Maternity Centers
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for Hospital Acquired Disease Testing market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Hospital Acquired Disease Testing Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the hospital acquired disease testing market include Abbott Laboratories,Diatherix Laboratories, LLC,bioMérieux S.A.,Life Technologies Corporation,Cantel Medical Corp.,Meridian Bioscience, Inc.,QIAGEN GmbH,Nordion Inc.,Roche Holding AG,Becton, Dickinson and Company. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.